Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | NPR1 | P16066 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790696 | 1.00 | PTK2 (0.41) | PTK2NR1H2NR1H3EGFRGPR55 | |
| SCHEMBL1792415 | 0.91 | GPR55 (0.45) | PTK2GPR55PTGS2CA1CA2 | |
| SCHEMBL1792002 | 0.90 | NR1H2 (0.35) | PTK2NR1H2NR1H3EGFRGPR55 | |
| SCHEMBL1792207 | 0.88 | PTGS2 (0.34) | PTK2NR1H2NR1H3EGFRGPR55 | |
| SCHEMBL1792277 | 0.87 | PTK2 (0.48) | PTK2PTGS2CA1CA2CA9 | |
| SCHEMBL1789249 | 0.87 | TAAR1 (0.34) | PTK2EGFRGPR55PTGS2CA1 | |
| SCHEMBL5107956 | 0.86 | GPR55 (0.38) | GPR55CA1CA2CA9PTGS1 | |
| SCHEMBL1791260 | 0.86 | PDE5A (0.37) | NR1H2PTGS2NPR1CA1CA2 | |
| SCHEMBL1794395 | 0.85 | EGFR (0.34) | NR1H2NR1H3EGFRGPR55PTGS2 | |
| SCHEMBL1794804 | 0.85 | EGFR (0.34) | NR1H2NR1H3EGFRGPR55PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | PTK2 4809/4885NR1H2 852/4885NR1H3 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.